Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance
The share of stand-alone prescription drug plans using coinsurance for preferred brand name drugs surged in recent years, exposing more patients to list prices that are often artificially inflated.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
Perspective
Assessing the Case Against Direct-to-Consumer Drug Advertisements
Featured Experts: Neeraj Sood
In The News View All
Tradeoffs
Trish interviewed on rising Medicare drug plan costs and narrowing options
Featured Experts: Erin Trish
NPR
Joyce interviewed about White House deal lowering prices on anti-obesity medications
Featured Experts: Geoffrey Joyce
CNBC
Lakdawalla discusses how White House obesity deal will broaden access
Featured Experts: Darius Lakdawalla
Tradeoffs Podcast
Lakdawalla interviewed about the uncertain impacts of the White House’s recent drug pricing deals
Featured Experts: Darius Lakdawalla
The New York Times
Employers face a growing challenge in managing the costs of specialty drugs, Ginsburg says
Featured Experts: Paul Ginsburg
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
